Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isotretinoin maintenance therapy for high-risk neuroblastoma
jRCTs031200107Active, not recruiting
- Sponsor
- Tokyo Metropolitan Government
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of isotretinoin in neuroblastoma and ganglioneuroblastoma (GNB), sponsored by Tokyo Metropolitan Government. Primary endpoint: Proportion of patients without any events for 1 year after starting isotretinoin. Started Jul 2021; status: active, not recruiting.
02
Drugs
isotretinoin
03
Conditions
neuroblastomaganglioneuroblastoma (GNB)
Beyond the preview
Go deeper on jRCTs031200107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200107.